Perceptive Advisors Llc - Oct 7, 2021 Form 4 Insider Report for Rain Therapeutics Inc. (RAIN)

Role: 10%+ Owner
Signature: /s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member
Stock symbol: RAIN
Transactions as of: Oct 7, 2021
Transactions value $: -$667,479
Form type: 4
Date filed: 10/13/2021, 05:47 PM
Previous filing: Sep 30, 2021
Next filing: Oct 14, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RAIN	Common Stock	Sale	-$194K	-13.1K	-0.52%	$14.80^*	2.52M	Oct 7, 2021	See Footnote	F1, F8
transaction	RAIN	Common Stock	Sale	-$4.3K	-286	-0.01%	$15.05^*	2.52M	Oct 7, 2021	See Footnote	F2, F8
transaction	RAIN	Common Stock	Sale	-$65K	-5.04K	-0.2%	$12.90^*	2.52M	Oct 8, 2021	See Footnote	F3, F8
transaction	RAIN	Common Stock	Sale	-$33.6K	-2.46K	-0.1%	$13.66^*	2.52M	Oct 8, 2021	See Footnote	F4, F8
transaction	RAIN	Common Stock	Sale	-$150K	-12.5K	-0.5%	$12.03^*	2.5M	Oct 11, 2021	See Footnote	F5, F8
transaction	RAIN	Common Stock	Sale	-$123K	-9.35K	-0.37%	$13.15^*	2.49M	Oct 11, 2021	See Footnote	F6, F8
transaction	RAIN	Common Stock	Sale	-$97.9K	-7.31K	-0.29%	$13.40^*	2.49M	Oct 12, 2021	See Footnote	F7, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.98, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
F2	The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.01 to $15.06, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
F3	The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.49 to $13.04, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
F4	The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.74, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
F5	The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.75 to $12.70, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
F6	The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.78 to $13.45, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
F7	The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.40, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range.
F8	The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.